Drugs / Plasmodium falciparum Malaria Protein 010 (FMP010)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00666380 | Apr → Dec 2008 | malaria | U.S. Army Medical Research and Development Command | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Plasmodium falciparum Malaria Protein 010 (FMP010) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00666380 ↗ |
| Known as | MSP1(42) | “Results from tandem Phase 1 studies evaluating the safety, reactogenicity and immunogenicity of the vaccine candidate antigen Plasmodium falciparum FVO merozoite surface...” PMID 23342996 ↗ Jan 2013 |
| Modality | Protein / enzyme biologic | “Vaccine antigen is a recombinant protein based on merozoite surface protein-1 (MSP-1) of FVO strain of Plasmodium falciparum” NCT00666380 ↗ |
| Route | Intramuscular | “administered intramuscularly” NCT00666380 ↗ |